radiology-multiomics-fusion

name

radiology-multiomics-fusion

description

Use when a radiology study must jointly model five data dimensions: imaging, clinical, pathology, bulk molecular omics, and single-cell or spatial omics. Selects early, intermediate, late, graph, or latent-factor fusion; handles block-specific preprocessing, missing modalities, batch and site effects, nested feature selection, ablation, interaction analysis, and external validation. Prevents high-dimensional fusion from outrunning the matched sample size.

Five-Dimensional Multi-Omics Fusion

Use this skill when all five dimensions — imaging, clinical, pathology, bulk molecular omics, and single-cell or spatial omics — are intended for joint prediction or integration. The analysable cohort is defined by patient-level linkage and modality availability, not by the largest source cohort. If fewer than five dimensions are used, label the study a reduced-dimensional variant and confirm that this module is still more appropriate than an existing focused module.

Core stance

• Availability before architecture. Build the patient-by-modality matrix and report the matched intersection before choosing a fusion method.
• Matched n limits complexity. The complete-case count, modality patterns, centers, and validation groups — plus endpoint events for supervised prediction — must support every fitted component. De-escalate when they do not.
• Earn the fusion by branch. Supervised models must beat clinical-only, single-modality, and simple regularized or late-fusion baselines. Unsupervised solutions must show stable, assignable, independently replicable structure.
• Nest the whole pipeline. Fit normalization, harmonization, embeddings, feature selection, imputation, fusion, and tuning using training data only.
• Respect the experimental unit. Cells, spots, regions, slides, and tiles are nested observations; donors or patients, not their subunits, determine the independent n.
• Missing blocks are design information. Distinguish structural, workflow, and quality-related absence; do not silently convert them into complete cases.
• Contribution is comparative, not causal. For supervised prediction, use single-block models, predictive ablation, conditional permutation, and pre-specified interactions. For unsupervised discovery, examine block-removal effects on cluster/factor alignment, stability, and assignment uncertainty. Neither establishes biological mechanism.
• Validate transportability. Preserve patient, site, batch, and time boundaries; external validation must reproduce the required modalities and processing route.

When to use

• A study intends to jointly model all five dimensions and must choose a defensible fusion architecture.
• The user asks about early, intermediate, late, graph, SNF, MOFA, DIABLO, iCluster, or deep multimodal fusion.
• Modality blocks are missing for some patients, or site and assay availability are entangled.
• A fusion manuscript needs leakage-safe preprocessing, ablation, contribution analysis, interaction testing, or site-aware validation.

Boundary and reciprocal handoff

• Use this module when fusion architecture and joint modeling across the intended five dimensions are the central problems.
• Use radiology-radiogenomics when imaging-to-molecular association, pathway or cell-state interpretation, or biological mechanism is the central workflow.
• If fewer than five dimensions are available, state that this is a reduced-dimensional variant. Consider radiology-radiogenomics for imaging-omics association, radiology-deep-learning for a primarily multimodal predictive architecture, or radiology-design when the cohort and question remain unsettled.
• Hand formal sample-size and performance-inference calculations to radiology-stats.

When to open extra files

File	Open when
references/fusion-architecture.md	Choosing among early, intermediate, late, SNF, MOFA, DIABLO, iCluster, graph, and deep multimodal approaches
references/missingness-and-validation.md	Handling missing blocks, complete-case bias, imputation, modality dropout, nested selection, site-aware validation, or ablation

Workflow

1. Build the patient-by-modality availability matrix. Put patients in rows and the five dimensions in columns; record usable/failed/missing status, acquisition time, lesion or specimen linkage, site, assay batch, and exclusion reason. Report total n, per-block n, every common availability pattern, and the all-block intersection.
2. Apply the matched-n feasibility gate. Check the matched n against proposed parameters, selected features, missingness patterns, centers, and intended validation; add endpoint-event adequacy for supervised prediction. If stable fitting and validation are not credible, reduce blocks or dimensions, use late fusion, restrict the aim to exploratory discovery, or collect more matched data.
3. Choose the supervised or unsupervised branch. For prediction, pre-specify the endpoint, estimand, clinical use, clinical-only model, strongest single-block model, and a simple regularized or late-fusion comparator. For SNF/MOFA/iCluster discovery, do not force an endpoint, calibration target, or predictive comparator: lock the discovery objective and tuning, assess resampling stability, define a prespecified cluster assignment rule, seek independent replication, and use outcomes only as secondary associations rather than to select clusters or factors.
4. Partition before preprocessing. Split by patient and preserve site, time, family, lesion, donor, and assay-batch dependencies. Keep cells, spots, regions, slides, and tiles from one donor or patient in the same fold; use patient/donor summaries, pseudobulk, or hierarchical/mixed-effects models when subunit-level data are retained. Define outer evaluation and inner tuning folds; keep external data untouched until the final locked evaluation.
5. Specify block-wise preprocessing. For each block, document QC, filtering, normalization, dimension reduction, batch/site handling, and feature stability. Estimate every data-dependent transform within the relevant training fold. For prospective prediction, require a frozen harmonization transform that can process an unseen patient or site without refitting on its distribution; label cohort-refitted harmonization as transductive and do not present it as deployable validation.
6. Justify the fusion architecture. Choose the simplest approach supported by the objective, matched n, block dimensions, missingness, need for interactions, interpretability, and deployment availability. Record why the rejected alternatives are less defensible.
7. Define missingness handling. Separate absent blocks from within-block missing values, assess missingness by endpoint and site, and bound imputation to supported quantities. Predictive/deployment pipelines must not use outcomes to impute inputs. Inferential multiple imputation may include outcomes under stated assumptions, with estimates and uncertainty pooled across imputations. Test pattern-specific or missing-modality performance. For deep models, modality dropout is a robustness device, not proof that an absent assay was reconstructed.

Output contract

Return the sections needed for the task:

1. Availability and feasibility — the five-block matrix summary, matched n, missingness patterns, and gate decision; include event counts only for a supervised endpoint when relevant.
2. Analysis branch — supervised endpoint, event adequacy, and baseline ladder; or unsupervised discovery objective, stability plan, assignment rule, and replication.
3. Fusion rationale — objective, selected architecture, data requirements, rejected alternatives, and failure controls.
4. Nested pipeline — split boundaries and block-specific preprocessing, selection, imputation, integration, and tuning.
5. Missingness plan — causes, bias assessment, supported handling, modality dropout or pattern-specific evaluation, and sensitivity analyses.
6. Contribution analysis — supervised single-block baselines, predictive leave-one-block-out ablation, conditional permutation, and pre-specified interactions; or unsupervised block-removal effects on cluster/factor alignment, stability, assignment uncertainty, and replication.
7. Validation and claims — for supervised prediction, internal and site-aware/external performance, calibration, uncertainty, and predictive ablation; for unsupervised discovery, stability, assignment uncertainty, block sensitivity, and independent replication, with outcomes secondary.
8. Author input needed — unresolved patient counts, linkage, batches, missingness causes, sites, external cohorts, deployment-time modalities, and event counts only when a supervised endpoint makes them relevant.

This skill supports study design and audit; it does not provide patient-specific diagnosis, treatment advice, or permission to fabricate missing assays or results.